Document is current

Article History

Accepted: 7 February 2021

First Online: 5 March 2021

Declarations

:

: No external funding was used in the preparation of this manuscript.

: R.B-S. has served as an advisor/consultant to Eli Lilly, Merck Sharp and Dohme, and Roche and has received honoraria from Bard Access, Bristol Myers Squib, Libbs, Eli Lilly, Novartis, Pfizer, Roche, and Zodiac and travel, accommodations, or expenses from Roche and Daiichi-Sankyo. SMT has received institutional research funding from Novartis, Genentech, Eli Lilly, Pfizer, Merck, Exelixis, Eisai, Bristol Meyers Squibb, AstraZeneca, Cyclacel, Immunomedics, Odonate, Sanofi, and Nektar and has served as an advisor/consultant to Novartis, Eli Lilly, Pfizer, Merck, AstraZeneca, Eisai, Puma, Genentech, Immunomedics, Nektar, Paxman, Athenex, OncoPep, Daiichi-Sankyo, G1 Therapeutics, Gilead, Silverback Therapeutics, Kyowa Kirin Pharmaceuticals, AbbVie, Sanofi, Seattle Genetics, Celldex, Bristol Myers Squibb, and NanoString.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.